OPKO Health (OPKO Health) Risk Assessment

View and export this data going back to 1995. Start your Free Trial

What is OPKO Health Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of OPKO Health is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of OPKO Health's Risk Assessment

For the Diagnostics & Research subindustry, OPKO Health's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OPKO Health's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's Risk Assessment distribution charts can be found below:

* The bar in red indicates where OPKO Health's Risk Assessment falls into.

OPKO Health (NAS:OPK) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

OPKO Health Risk Assessment Related Terms

Thank you for viewing the detailed overview of OPKO Health's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

OPKO Health (OPKO Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OPKO Health Inc (NAS:OPK) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

OPK:Mexico OPK:Israel XCY:Germany XCY:Germany

Address

4400 Biscayne Boulevard, Miami, FL, USA, 33137

Website

https://www.opko.com

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a speciality active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.

Executives

Frost Phillip Md Et Al	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Hsiao Jane Ph D	director	4400 BISCAYNE BLVD, MIAMI FL 33137
Gary J. Nabel	director, officer: Chief Innovation Officer	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Elias A. Zerhouni	director, officer: Vice Chairman and President	2099 PENNSYLVANIA AVENUE, NW 12TH FLOOR, WASHINGTON DC 20006
John A Paganelli	director, other: Chairman of the Board	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Alexis Borisy	director	C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 16TH FLOOR, CAMBRIDGE MA 02142
Jon R Cohen	director, officer: SVP OPKO; Exec Chairman BRLI	C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Prem A Lachman	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Roger Md Medel	director	1301 CONCORD TERRACE, SUNRISE FL 33323
Rulfo Fernando Hernandez	officer: CAO, Treasurer	C/O OPKO HEALTH INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Anthony J Japour	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
Robert Scott Fishel	director	C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Adam Logal	officer: Exec.Dir .of Fin., CAO,Treas.	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137